NasdaqCM:CORTPharmaceuticals
A Look At Corcept Therapeutics (CORT) Valuation After Legal And FDA Setbacks Reshape Expectations
Earnings and legal developments reshape the Corcept Therapeutics (CORT) story
Corcept Therapeutics (CORT) is back in focus after investors digested a mix of legal and regulatory headlines, including a securities class action tied to disclosures around its relacorilant program and the FDA’s rejection of the drug.
The lawsuit centers on allegations that Corcept and certain executives misrepresented the strength of clinical evidence for relacorilant in hypercortisolism and the feedback received...